Open Access

Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report

  • Authors:
    • Arisu Ishihara
    • Hiroko Kuwabara
    • Emi Yasuda
    • Tsuyoshi Jinnin
    • Masaaki Higashino
    • Toshitaka Nagao
    • Shin-Ichi Haginomori
    • Yoshinobu Hirose
  • View Affiliations

  • Published online on: February 21, 2025     https://doi.org/10.3892/br.2025.1951
  • Article Number: 73
  • Copyright: © Ishihara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study reports the case of a 25‑year‑old male patient with salivary gland secretory carcinoma (SC) with the ETV6::RET gene fusion. The patient presented with a left parotid mass and was treated using a superficial parotidectomy. Histological analysis of the tumor demonstrated a combination of cystic, follicular and trabecular patterns in cells, with eosinophilic secretions and a vacuolated cytoplasm. Tumor cells exhibited infiltrative growth into muscle and nerve tissues, accompanied by central stromal hyalinized sclerosis. Immunohistochemically, the tumor cells were positive for S‑100, mammaglobin and GATA binding protein 3, and negative for DOG1. The results of the present case demonstrated that the patient possessed SC with the ETV6::RET gene fusion. Following the operation, the patient underwent radiotherapy, leading to a disease‑free state at the last follow‑up at 1 year and 3 months following surgery. A comprehensive review of 21 SC cases with this gene fusion, including the case reported in the present study, demonstrated that invasive growth, neural and lymphovascular invasion and hyalinized sclerosis were frequently seen on histology, and 11 cases (52%) exhibited advanced‑stage disease (>T3 or M1). Thus, salivary gland SC with an ETV6::RET fusion may show infiltrative growth and may be more aggressive compared with salivary gland SC with an ETV6::NTRK3 fusion, which is often associated with an indolent clinical course. Therefore, confirmation of the genetic profile of SC is crucial for the prediction of patient prognosis and administration of an effective therapeutic course.

Related Articles

Journal Cover

April-2025
Volume 22 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ishihara A, Kuwabara H, Yasuda E, Jinnin T, Higashino M, Nagao T, Haginomori S and Hirose Y: Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report. Biomed Rep 22: 73, 2025.
APA
Ishihara, A., Kuwabara, H., Yasuda, E., Jinnin, T., Higashino, M., Nagao, T. ... Hirose, Y. (2025). Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report. Biomedical Reports, 22, 73. https://doi.org/10.3892/br.2025.1951
MLA
Ishihara, A., Kuwabara, H., Yasuda, E., Jinnin, T., Higashino, M., Nagao, T., Haginomori, S., Hirose, Y."Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report". Biomedical Reports 22.4 (2025): 73.
Chicago
Ishihara, A., Kuwabara, H., Yasuda, E., Jinnin, T., Higashino, M., Nagao, T., Haginomori, S., Hirose, Y."Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report". Biomedical Reports 22, no. 4 (2025): 73. https://doi.org/10.3892/br.2025.1951